SF3B1 and endometrial cancer: Moreover, consistent with minimal SF3B1 protein levels, RL-95-2 cells showed diminished impact of SF3B1 knockdown or PLAD-B treatment on cell viability and migration in comparison to other three endometrial cancer cells that have robust SF3B1 protein levels (Fig. S2).